Charles S. Berkman
2018 - Ligand Pharmaceuticals
In 2018, Charles S. Berkman earned a total compensation of $1.7M as Senior Vice President and General Counsel at Ligand Pharmaceuticals, a 16% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $177,100 |
|---|---|
| Option Awards | $533,547 |
| Salary | $402,500 |
| Stock Awards | $623,961 |
| Other | $6,471 |
| Total | $1,743,579 |
Berkman received $624K in stock awards, accounting for 36% of the total pay in 2018.
Berkman also received $177.1K in non-equity incentive plan, $533.5K in option awards, $402.5K in salary and $6.5K in other compensation.
Rankings
In 2018, Charles S. Berkman's compensation ranked 6,416th out of 14,244 executives tracked by ExecPay. In other words, Berkman earned more than 55.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,416 out of 14,244 | 55th |
Division Manufacturing | 2,452 out of 5,765 | 58th |
Major group Chemicals And Allied Products | 913 out of 2,128 | 57th |
Industry group Drugs | 767 out of 1,817 | 58th |
Industry Pharmaceutical Preparations | 595 out of 1,391 | 57th |
Source: SEC filing on April 24, 2020.
Berkman's colleagues
We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2018.